Exploring the relationship between novel serum inflammatory markers, non-traditional lipid parameters, and in-stent restenosis after percutaneous coronary intervention: a single-center retrospective study - Scorecard - MDSpire
Advertisement
Exploring the relationship between novel serum inflammatory markers, non-traditional lipid parameters, and in-stent restenosis after percutaneous coronary intervention: a single-center retrospective study
Clinical Scorecard: Investigating the association of innovative serum inflammatory markers and atypical lipid profiles with in-stent restenosis following percutaneous coronary intervention: a retrospective analysis from a single center
At a Glance
Category
Detail
Condition
In-stent restenosis (ISR)
Key Mechanisms
Inflammation and lipid metabolism
Target Population
Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Care Setting
Single-center retrospective study
Key Highlights
ISR remains a significant cause of PCI failure despite advances in DES technology.
Higher levels of CRI-II and LCI are associated with ISR.
ROC analysis indicates limited discriminatory ability of CRI-II and LCI for ISR risk stratification.
Novel inflammatory markers were not independently associated with ISR.
The study included 564 patients with follow-up coronary angiography.
Guideline-Based Recommendations
Diagnosis
Utilize follow-up coronary angiography for ISR assessment post-PCI.
Management
Consider CRI-II and LCI as potential indicators for ISR risk, though not ready for clinical recommendation.
Monitoring & Follow-up
Monitor inflammatory indices and lipid profiles in patients post-PCI.
Risks
Recurrent cardiovascular events linked to ISR include unstable angina and myocardial infarction.
Patient & Prescribing Data
564 patients with coronary heart disease undergoing DES implantation.
Focus on comprehensive assessment of inflammatory and lipid parameters for ISR risk.
Clinical Best Practices
Incorporate both traditional and non-traditional lipid parameters in patient evaluations.
Assess inflammatory markers alongside lipid profiles for a holistic view of ISR risk.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
